From the Division of Rheumatology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong; Department of Medicine, Hong Kong Sanatorium and Hospital, Hong Kong SAR, China; Rheumatology Unit, University of Pisa, Pisa, Italy; Department of Rheumatology, Institute of Rheumatology, Prague, Czech Republic; Division of Rheumatology, School of Medicine, Marmara University, Istanbul, Turkey; Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University, Brest; Department of Rheumatology, AP-HP, Hôpital Ambroise Paré, Rheumatology Department, Boulogne-Billancourt; INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University, Saint-Quentin en Yvelines, France; Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany; Department of Rheumatology, Université Catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint Luc, Brussels, Belgium; School of Medicine and Pharmacology, University of Western Australia, Perth, Australia; Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark; Department of Rheumatology, MC Groep, Lelystad, the Netherlands.
P.C. Wong, MD, Division of Rheumatology, Department of Medicine and Therapeutics, The Chinese University of Hong Kong; G. Lee, MD, Department of Medicine, Hong Kong Sanatorium and Hospital; A. Delle Sedie, MD, Rheumatology Unit, University of Pisa; P. Hanova, MD, PhD, Department of Rheumatology, Institute of Rheumatology; N. Inanc, MD, Division of Rheumatology, School of Medicine, Marmara University; S. Jousse-Joulin, MD, Rheumatology Department, Cavale Blanche Hospital and Brest Occidentale University; S. Ohrndorf, MD, Department of Rheumatology and Clinical Immunology, Charite University Hospital; M.S. Stoenoiu, MD, PhD, Department of Rheumatology, Université Catholique de Louvain, Institut de Recherche Expérimentale et Clinique, Cliniques Universitaires Saint Luc; H.I. Keen, MD, PhD, School of Medicine and Pharmacology, University of Western Australia; L. Terslev, MD, PhD, Center for Rheumatology and Spine Diseases, Rigshospitalet; M.A. D'Agostino, MD, PhD, Department of Rheumatology, AP-HP, Hôpital Ambroise Paré, Rheumatology Department, and INSERM U1173, Laboratoire d'Excellence INFLAMEX, UFR Simone Veil, Versailles-Saint-Quentin University; G.A. Bruyn, MD, PhD, Department of Rheumatology, MC Groep.
J Rheumatol. 2019 Oct;46(10):1379-1387. doi: 10.3899/jrheum.181087. Epub 2019 Jun 15.
To identify and synthesize the best available evidence on the application of musculoskeletal (MSK) ultrasound (US) in patients with systemic lupus erythematosus (SLE) and to present the measurement properties of US in different elementary lesions and pathologies.
A systematic literature search of PubMed, Embase, and the Cochrane Library was performed. Original articles were included that were published in English between August 1, 2014, and December 31, 2018, reporting US, Doppler, synovitis, joint effusion, bone erosion, tenosynovitis, and enthesitis in patients with SLE. Data extraction focused on the definition and quantification of US-detected synovitis, joint effusion, bone erosion, tenosynovitis, enthesitis, and the measurement properties of US according to the OMERACT Filter 2.1 instruments selection.
Of the 143 identified articles, 15 were included. Most articles were cross-sectional studies (14/15, 93%). The majority of the studies used the OMERACT definitions for ultrasonographic pathology. Regarding the measurement properties of US in different elementary lesions and pathologies, all studies dealt with face validity, content validity, and feasibility. Most studies achieved construct validity. Concerning the reliability of image reading, 1 study (1/15, 7%) assessed both intraobserver and interobserver reliability. For image acquisition, 4 studies (4/15, 27%) evaluated interobserver reliability and none had evaluated intraobserver reliability. Criterion validity was assessed in 1 study (1/15, 7%). Responsiveness was not considered in any of the studies.
This literature review demonstrates the need for further research and validation work to define the involvement of US as an outcome measurement instrument for the MSK manifestations in patients with SLE.
确定并综合有关肌肉骨骼(MSK)超声(US)在系统性红斑狼疮(SLE)患者中应用的最佳证据,并介绍 US 在不同基本病变和病理中的测量性能。
对 PubMed、Embase 和 Cochrane 图书馆进行了系统的文献检索。纳入了 2014 年 8 月 1 日至 2018 年 12 月 31 日期间以英文发表的、报告 SLE 患者 US、多普勒、滑膜炎、关节积液、骨侵蚀、腱鞘炎和肌腱附着点炎的原始文章。数据提取重点是根据 OMERACT Filter 2.1 仪器选择标准,确定和量化 US 检测到的滑膜炎、关节积液、骨侵蚀、腱鞘炎、肌腱附着点炎的定义和定量。
在 143 篇确定的文章中,有 15 篇被纳入。大多数文章为横断面研究(14/15,93%)。大多数研究采用了 OMERACT 超声病理定义。关于不同基本病变和病理中的 US 测量性能,所有研究均涉及表面有效性、内容有效性和可行性。大多数研究达到了结构有效性。关于图像阅读的可靠性,有 1 项研究(1/15,7%)评估了观察者内和观察者间的可靠性。对于图像采集,有 4 项研究(4/15,27%)评估了观察者间的可靠性,没有研究评估观察者内的可靠性。有 1 项研究(1/15,7%)评估了标准有效性。没有研究考虑反应性。
本文献综述表明,需要进一步开展研究和验证工作,以确定 US 作为 SLE 患者 MSK 表现的结局测量工具的参与度。